Illinois General Assembly - Full Text of HB0333
Illinois General Assembly

Previous General Assemblies

Full Text of HB0333  96th General Assembly

HB0333 96TH GENERAL ASSEMBLY


 


 
96TH GENERAL ASSEMBLY
State of Illinois
2009 and 2010
HB0333

 

Introduced 1/27/2009, by Rep. Jack D. Franks

 

SYNOPSIS AS INTRODUCED:
 
See Index

    Creates the Prescription Drug Repository Program Act. Requires the Department of Public Health to establish a prescription drug repository program, under which any person may donate a prescription drug or supplies needed to administer a prescription drug for use by an individual who meets eligibility criteria specified by the Department. Sets forth requirements that prescription drugs or supplies must meet in order to be accepted and dispensed under the program. Prohibits the resale of drugs or supplies donated under the program. Provides for civil and criminal immunity for drug and supply manufacturers and individuals. Amends the Pharmacy Practice Act and other Acts to provide that persons engaged in certain activities to the extent permitted or required under the Prescription Drug Repository Program Act are exempt from provisions of those other Acts that might prohibit or otherwise regulate such activity. Amends the Counties Code, the Illinois Food, Drug and Cosmetic Act, and the Illinois Controlled Substances Act. Provides that a coroner may take possession of prescription drugs and controlled substances associated or identified with a person whose death is being investigated.


LRB096 03203 DRJ 13220 b

FISCAL NOTE ACT MAY APPLY

 

 

A BILL FOR

 

HB0333 LRB096 03203 DRJ 13220 b

1     AN ACT concerning health.
 
2     Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
 
4     Section 1. Short title. This Act may be cited as the
5 Prescription Drug Repository Program Act.
 
6     Section 5. Definitions. In this Act:
7     "Department" means the Department of Public Health.
8     "Dispense" has the meaning given to that term in the
9 Pharmacy Practice Act.
10     "Pharmacist" means an individual licensed to engage in the
11 practice of pharmacy under the Pharmacy Practice Act.
12     "Pharmacy" means a pharmacy registered in this State under
13 the Pharmacy Practice Act.
14     "Practitioner" means a person licensed in this State to
15 prescribe and administer drugs or licensed in another state and
16 recognized by this State as a person authorized to prescribe
17 and administer drugs.
18     "Prescription drug" means any prescribed drug that may be
19 legally dispensed by a pharmacy. "Prescription drug" does not
20 include drugs for the treatment of cancer that can only be
21 dispensed to a patient registered with the drug manufacturer in
22 accordance with federal Food and Drug Administration
23 requirements.

 

 

HB0333 - 2 - LRB096 03203 DRJ 13220 b

1     "Program" means the prescription drug repository program
2 established under this Act.
 
3     Section 10. Prescription drug repository program. The
4 Department shall establish and maintain a prescription drug
5 repository program, under which any person may donate a
6 prescription drug or supplies needed to administer a
7 prescription drug for use by an individual who meets
8 appropriate eligibility criteria. Donations may be made on the
9 premises of a pharmacy that elects to participate in the
10 program and meets appropriate requirements. The pharmacy may
11 charge an individual who receives a prescription drug or
12 supplies needed to administer a prescription drug under this
13 Act a handling fee that may not exceed an appropriate amount. A
14 pharmacy that receives a donated prescription drug or supplies
15 needed to administer a prescription drug under this Act may
16 distribute the prescription drug or supplies to another
17 eligible pharmacy for use under the program.
 
18     Section 15. Requirements for accepting and dispensing
19 prescription drugs and supplies. A prescription drug or
20 supplies needed to administer a prescription drug may be
21 accepted and dispensed under the program only if all of the
22 following requirements are met:
23         (1) The prescription drug or supplies needed to
24     administer a prescription drug are in their original,

 

 

HB0333 - 3 - LRB096 03203 DRJ 13220 b

1     unopened, sealed, and tamper-evident unit-dose packaging
2     or, if packaged in single-unit doses, the single-unit-dose
3     packaging is unopened.
4         (2) The prescription drug bears an expiration date that
5     is later than 6 months after the date that the drug was
6     donated.
7         (3) The prescription drug or supplies needed to
8     administer a prescription drug are not adulterated or
9     misbranded, as determined by a pharmacist employed by, or
10     under contract with, the pharmacy where the drug or
11     supplies are accepted or dispensed. The pharmacist must
12     inspect the drug or supplies before the drug or supplies
13     are dispensed.
14         (4) The prescription drug or supplies needed to
15     administer a prescription drug are prescribed by a
16     practitioner for use by an eligible individual.
 
17     Section 20. Resale of donated drugs or supplies prohibited.
18 No prescription drug or supplies needed to administer a
19 prescription drug that are donated for use under this Act may
20 be resold.
 
21     Section 25. Participation in program not required. Nothing
22 in this Act requires that a pharmacy or pharmacist participate
23 in the prescription drug repository program.
 

 

 

HB0333 - 4 - LRB096 03203 DRJ 13220 b

1     Section 30. Immunity.
2     (a) Unless the manufacturer's conduct is wilful and wanton,
3 a manufacturer of a drug or supply is not subject to criminal
4 or civil liability for injury, death, or loss to a person or
5 property for matters related to the donation, acceptance, or
6 dispensing of a prescription drug or supply manufactured by the
7 manufacturer that is donated by any person under this Act.
8     (b) Unless the person's conduct is wilful and wanton, a
9 person is immune from civil liability for injury to or the
10 death of the individual to whom the prescription drug or supply
11 is dispensed and may not be found guilty of unprofessional
12 conduct for his or her acts or omissions related to donating,
13 accepting, distributing, or dispensing a prescription drug or
14 supply under this Act.
 
15     Section 35. Rules. The Department may adopt rules
16 establishing standards for the disposal of drugs not accepted
17 under the program.
 
18     Section 90. The Counties Code is amended by changing
19 Section 3-3013 as follows:
 
20     (55 ILCS 5/3-3013)  (from Ch. 34, par. 3-3013)
21     Sec. 3-3013. Preliminary investigations; blood and urine
22 analysis; summoning jury. Every coroner, whenever, as soon as
23 he knows or is informed that the dead body of any person is

 

 

HB0333 - 5 - LRB096 03203 DRJ 13220 b

1 found, or lying within his county, whose death is suspected of
2 being:
3         (a) A sudden or violent death, whether apparently
4     suicidal, homicidal or accidental, including but not
5     limited to deaths apparently caused or contributed to by
6     thermal, traumatic, chemical, electrical or radiational
7     injury, or a complication of any of them, or by drowning or
8     suffocation, or as a result of domestic violence as defined
9     in the Illinois Domestic Violence Act of 1986;
10         (b) A maternal or fetal death due to abortion, or any
11     death due to a sex crime or a crime against nature;
12         (c) A death where the circumstances are suspicious,
13     obscure, mysterious or otherwise unexplained or where, in
14     the written opinion of the attending physician, the cause
15     of death is not determined;
16         (d) A death where addiction to alcohol or to any drug
17     may have been a contributory cause; or
18         (e) A death where the decedent was not attended by a
19     licensed physician;
20 shall go to the place where the dead body is, and take charge
21 of the same and shall make a preliminary investigation into the
22 circumstances of the death. In the case of death without
23 attendance by a licensed physician the body may be moved with
24 the coroner's consent from the place of death to a mortuary in
25 the same county. Coroners in their discretion shall notify such
26 physician as is designated in accordance with Section 3-3014 to

 

 

HB0333 - 6 - LRB096 03203 DRJ 13220 b

1 attempt to ascertain the cause of death, either by autopsy or
2 otherwise.
3     In connection with an investigation under this Division,
4 the coroner may take possession of prescription drugs and
5 controlled substances associated or identified with a person
6 whose death is being investigated. The coroner shall inventory
7 the prescription drugs and controlled substances taken during
8 an investigation. The coroner shall prepare and maintain a
9 record of the disposition of the prescription drugs and
10 controlled substances. If the prescription drugs and
11 controlled substances will be disposed of by the coroner, then
12 the coroner shall dispose of the prescription drugs and
13 controlled substances by a safe and environmentally sound
14 method. For the purpose of this paragraph, "prescription drug"
15 has the meaning set forth under Section 2.37 of the Illinois
16 Food, Drug and Cosmetic Act. For the purpose of this paragraph,
17 "controlled substance" has the meaning set forth under
18 subsection (f) of Section 102 of the Illinois Controlled
19 Substances Act. Nothing in this paragraph shall be construed to
20 authorize or require a coroner to take actions that would
21 interfere with a criminal investigation or prosecution.
22     In cases of accidental death involving a motor vehicle in
23 which the decedent was (1) the operator or a suspected operator
24 of a motor vehicle, or (2) a pedestrian 16 years of age or
25 older, the coroner shall require that a blood specimen of at
26 least 30 cc., and if medically possible a urine specimen of at

 

 

HB0333 - 7 - LRB096 03203 DRJ 13220 b

1 least 30 cc. or as much as possible up to 30 cc., be withdrawn
2 from the body of the decedent in a timely fashion after the
3 accident causing his death, by such physician as has been
4 designated in accordance with Section 3-3014, or by the coroner
5 or deputy coroner or a qualified person designated by such
6 physician, coroner, or deputy coroner. If the county does not
7 maintain laboratory facilities for making such analysis, the
8 blood and urine so drawn shall be sent to the Department of
9 State Police or any other accredited or State-certified
10 laboratory for analysis of the alcohol, carbon monoxide, and
11 dangerous or narcotic drug content of such blood and urine
12 specimens. Each specimen submitted shall be accompanied by
13 pertinent information concerning the decedent upon a form
14 prescribed by such laboratory. Any person drawing blood and
15 urine and any person making any examination of the blood and
16 urine under the terms of this Division shall be immune from all
17 liability, civil or criminal, that might otherwise be incurred
18 or imposed.
19     In all other cases coming within the jurisdiction of the
20 coroner and referred to in subparagraphs (a) through (e) above,
21 blood, and whenever possible, urine samples shall be analyzed
22 for the presence of alcohol and other drugs. When the coroner
23 suspects that drugs may have been involved in the death, either
24 directly or indirectly, a toxicological examination shall be
25 performed which may include analyses of blood, urine, bile,
26 gastric contents and other tissues. When the coroner suspects a

 

 

HB0333 - 8 - LRB096 03203 DRJ 13220 b

1 death is due to toxic substances, other than drugs, the coroner
2 shall consult with the toxicologist prior to collection of
3 samples. Information submitted to the toxicologist shall
4 include information as to height, weight, age, sex and race of
5 the decedent as well as medical history, medications used by
6 and the manner of death of decedent.
7     When the coroner or medical examiner finds that the cause
8 of death is due to homicidal means, the coroner or medical
9 examiner shall cause blood and buccal specimens (tissue may be
10 submitted if no uncontaminated blood or buccal specimen can be
11 obtained), whenever possible, to be withdrawn from the body of
12 the decedent in a timely fashion. Within 45 days after the
13 collection of the specimens, the coroner or medical examiner
14 shall deliver those specimens, dried, to the Illinois
15 Department of State Police, Division of Forensic Services, for
16 analysis and categorizing into genetic marker groupings to be
17 maintained by the Illinois Department of State Police in the
18 State central repository in the same manner, and subject to the
19 same conditions, as provided in Section 5-4-3 of the Unified
20 Code of Corrections. The requirements of this paragraph are in
21 addition to any other findings, specimens, or information that
22 the coroner or medical examiner is required to provide during
23 the conduct of a criminal investigation.
24     In all counties, in cases of apparent suicide, homicide, or
25 accidental death or in other cases, within the discretion of
26 the coroner, the coroner may summon 8 persons of lawful age

 

 

HB0333 - 9 - LRB096 03203 DRJ 13220 b

1 from those persons drawn for petit jurors in the county. The
2 summons shall command these persons to present themselves
3 personally at such a place and time as the coroner shall
4 determine, and may be in any form which the coroner shall
5 determine and may incorporate any reasonable form of request
6 for acknowledgement which the coroner deems practical and
7 provides a reliable proof of service. The summons may be served
8 by first class mail. From the 8 persons so summoned, the
9 coroner shall select 6 to serve as the jury for the inquest.
10 Inquests may be continued from time to time, as the coroner may
11 deem necessary. The 6 jurors selected in a given case may view
12 the body of the deceased. If at any continuation of an inquest
13 one or more of the original jurors shall be unable to continue
14 to serve, the coroner shall fill the vacancy or vacancies. A
15 juror serving pursuant to this paragraph shall receive
16 compensation from the county at the same rate as the rate of
17 compensation that is paid to petit or grand jurors in the
18 county. The coroner shall furnish to each juror without fee at
19 the time of his discharge a certificate of the number of days
20 in attendance at an inquest, and, upon being presented with
21 such certificate, the county treasurer shall pay to the juror
22 the sum provided for his services.
23     In counties which have a jury commission, in cases of
24 apparent suicide or homicide or of accidental death, the
25 coroner may conduct an inquest. The jury commission shall
26 provide at least 8 jurors to the coroner, from whom the coroner

 

 

HB0333 - 10 - LRB096 03203 DRJ 13220 b

1 shall select any 6 to serve as the jury for the inquest.
2 Inquests may be continued from time to time as the coroner may
3 deem necessary. The 6 jurors originally chosen in a given case
4 may view the body of the deceased. If at any continuation of an
5 inquest one or more of the 6 jurors originally chosen shall be
6 unable to continue to serve, the coroner shall fill the vacancy
7 or vacancies. At the coroner's discretion, additional jurors to
8 fill such vacancies shall be supplied by the jury commission. A
9 juror serving pursuant to this paragraph in such county shall
10 receive compensation from the county at the same rate as the
11 rate of compensation that is paid to petit or grand jurors in
12 the county.
13     In addition, in every case in which domestic violence is
14 determined to be a contributing factor in a death, the coroner
15 shall report the death to the Department of State Police.
16     All deaths in State institutions and all deaths of wards of
17 the State in private care facilities or in programs funded by
18 the Department of Human Services under its powers relating to
19 mental health and developmental disabilities or alcoholism and
20 substance abuse or funded by the Department of Children and
21 Family Services shall be reported to the coroner of the county
22 in which the facility is located. If the coroner has reason to
23 believe that an investigation is needed to determine whether
24 the death was caused by maltreatment or negligent care of the
25 ward of the State, the coroner may conduct a preliminary
26 investigation of the circumstances of such death as in cases of

 

 

HB0333 - 11 - LRB096 03203 DRJ 13220 b

1 death under circumstances set forth in paragraphs (a) through
2 (e) of this Section.
3 (Source: P.A. 94-924, eff. 1-1-07; 95-484, eff. 6-1-08.)
 
4     Section 91. The Pharmacy Practice Act is amended by
5 changing Section 4 as follows:
 
6     (225 ILCS 85/4)  (from Ch. 111, par. 4124)
7     (Section scheduled to be repealed on January 1, 2018)
8     Sec. 4. Exemptions. Nothing contained in any Section of
9 this Act shall apply to, or in any manner interfere with:
10     (a) the lawful practice of any physician licensed to
11 practice medicine in all of its branches, dentist, podiatrist,
12 veterinarian, or therapeutically or diagnostically certified
13 optometrist within the limits of his or her license, or prevent
14 him or her from supplying to his or her bona fide patients such
15 drugs, medicines, or poisons as may seem to him appropriate;
16     (b) the sale of compressed gases;
17     (c) the sale of patent or proprietary medicines and
18 household remedies when sold in original and unbroken packages
19 only, if such patent or proprietary medicines and household
20 remedies be properly and adequately labeled as to content and
21 usage and generally considered and accepted as harmless and
22 nonpoisonous when used according to the directions on the
23 label, and also do not contain opium or coca leaves, or any
24 compound, salt or derivative thereof, or any drug which,

 

 

HB0333 - 12 - LRB096 03203 DRJ 13220 b

1 according to the latest editions of the following authoritative
2 pharmaceutical treatises and standards, namely, The United
3 States Pharmacopoeia/National Formulary (USP/NF), the United
4 States Dispensatory, and the Accepted Dental Remedies of the
5 Council of Dental Therapeutics of the American Dental
6 Association or any or either of them, in use on the effective
7 date of this Act, or according to the existing provisions of
8 the Federal Food, Drug, and Cosmetic Act and Regulations of the
9 Department of Health and Human Services, Food and Drug
10 Administration, promulgated thereunder now in effect, is
11 designated, described or considered as a narcotic, hypnotic,
12 habit forming, dangerous, or poisonous drug;
13     (d) the sale of poultry and livestock remedies in original
14 and unbroken packages only, labeled for poultry and livestock
15 medication;
16     (e) the sale of poisonous substances or mixture of
17 poisonous substances, in unbroken packages, for nonmedicinal
18 use in the arts or industries or for insecticide purposes;
19 provided, they are properly and adequately labeled as to
20 content and such nonmedicinal usage, in conformity with the
21 provisions of all applicable federal, state and local laws and
22 regulations promulgated thereunder now in effect relating
23 thereto and governing the same, and those which are required
24 under such applicable laws and regulations to be labeled with
25 the word "Poison", are also labeled with the word "Poison"
26 printed thereon in prominent type and the name of a readily

 

 

HB0333 - 13 - LRB096 03203 DRJ 13220 b

1 obtainable antidote with directions for its administration;
2     (f) the delegation of limited prescriptive authority by a
3 physician licensed to practice medicine in all its branches to
4 a physician assistant under Section 7.5 of the Physician
5 Assistant Practice Act of 1987. This delegated authority under
6 Section 7.5 of the Physician Assistant Practice Act of 1987 may
7 but is not required to include prescription of controlled
8 substances, as defined in Article II of the Illinois Controlled
9 Substances Act, in accordance with written guidelines; and
10     (g) the The delegation of prescriptive authority by a
11 physician licensed to practice medicine in all its branches to
12 an advanced practice nurse in accordance with a written
13 collaborative agreement under Section 65-35 of the Nurse
14 Practice Act. This authority, which is delegated under Section
15 65-40 of the Nurse Practice Act, may but is not required to
16 include the prescription of Schedule III, IV, or V controlled
17 substances as defined in Article II of the Illinois Controlled
18 Substances Act; and .
19     (h) the donation or acceptance, or the packaging,
20 repackaging, or labeling, of prescription drugs to the extent
21 permitted or required under the Prescription Drug Repository
22 Program Act.
23 (Source: P.A. 95-639, eff. 10-5-07.)
 
24     Section 92. The Wholesale Drug Distribution Licensing Act
25 is amended by changing Section 15 as follows:
 

 

 

HB0333 - 14 - LRB096 03203 DRJ 13220 b

1     (225 ILCS 120/15)  (from Ch. 111, par. 8301-15)
2     (Section scheduled to be repealed on January 1, 2013)
3     Sec. 15. Definitions. As used in this Act:
4     "Authentication" means the affirmative verification,
5 before any wholesale distribution of a prescription drug
6 occurs, that each transaction listed on the pedigree has
7 occurred.
8     "Authorized distributor of record" means a wholesale
9 distributor with whom a manufacturer has established an ongoing
10 relationship to distribute the manufacturer's prescription
11 drug. An ongoing relationship is deemed to exist between a
12 wholesale distributor and a manufacturer when the wholesale
13 distributor, including any affiliated group of the wholesale
14 distributor, as defined in Section 1504 of the Internal Revenue
15 Code, complies with the following:
16         (1) The wholesale distributor has a written agreement
17     currently in effect with the manufacturer evidencing the
18     ongoing relationship; and
19         (2) The wholesale distributor is listed on the
20     manufacturer's current list of authorized distributors of
21     record, which is updated by the manufacturer on no less
22     than a monthly basis.
23     "Blood" means whole blood collected from a single donor and
24 processed either for transfusion or further manufacturing.
25     "Blood component" means that part of blood separated by

 

 

HB0333 - 15 - LRB096 03203 DRJ 13220 b

1 physical or mechanical means.
2     "Board" means the State Board of Pharmacy of the Department
3 of Professional Regulation.
4     "Chain pharmacy warehouse" means a physical location for
5 prescription drugs that acts as a central warehouse and
6 performs intracompany sales or transfers of the drugs to a
7 group of chain or mail order pharmacies that have the same
8 common ownership and control. Notwithstanding any other
9 provision of this Act, a chain pharmacy warehouse shall be
10 considered part of the normal distribution channel.
11     "Co-licensed partner or product" means an instance where
12 one or more parties have the right to engage in the
13 manufacturing or marketing of a prescription drug, consistent
14 with the FDA's implementation of the Prescription Drug
15 Marketing Act.
16     "Department" means the Department of Financial and
17 Professional Regulation.
18     "Drop shipment" means the sale of a prescription drug to a
19 wholesale distributor by the manufacturer of the prescription
20 drug or that manufacturer's co-licensed product partner, that
21 manufacturer's third party logistics provider, or that
22 manufacturer's exclusive distributor or by an authorized
23 distributor of record that purchased the product directly from
24 the manufacturer or one of these entities whereby the wholesale
25 distributor or chain pharmacy warehouse takes title but not
26 physical possession of such prescription drug and the wholesale

 

 

HB0333 - 16 - LRB096 03203 DRJ 13220 b

1 distributor invoices the pharmacy, chain pharmacy warehouse,
2 or other person authorized by law to dispense or administer
3 such drug to a patient and the pharmacy, chain pharmacy
4 warehouse, or other authorized person receives delivery of the
5 prescription drug directly from the manufacturer, that
6 manufacturer's third party logistics provider, or that
7 manufacturer's exclusive distributor or from an authorized
8 distributor of record that purchased the product directly from
9 the manufacturer or one of these entities.
10     "Drug sample" means a unit of a prescription drug that is
11 not intended to be sold and is intended to promote the sale of
12 the drug.
13     "Facility" means a facility of a wholesale distributor
14 where prescription drugs are stored, handled, repackaged, or
15 offered for sale.
16     "FDA" means the United States Food and Drug Administration.
17     "Manufacturer" means a person licensed or approved by the
18 FDA to engage in the manufacture of drugs or devices,
19 consistent with the definition of "manufacturer" set forth in
20 the FDA's regulations and guidances implementing the
21 Prescription Drug Marketing Act. "Manufacturer" does not
22 include anyone who is engaged in the packaging, repackaging, or
23 labeling of prescription drugs only to the extent required
24 under the Prescription Drug Repository Program Act.
25     "Manufacturer's exclusive distributor" means anyone who
26 contracts with a manufacturer to provide or coordinate

 

 

HB0333 - 17 - LRB096 03203 DRJ 13220 b

1 warehousing, distribution, or other services on behalf of a
2 manufacturer and who takes title to that manufacturer's
3 prescription drug, but who does not have general responsibility
4 to direct the sale or disposition of the manufacturer's
5 prescription drug. A manufacturer's exclusive distributor must
6 be licensed as a wholesale distributor under this Act and, in
7 order to be considered part of the normal distribution channel,
8 must also be an authorized distributor of record.
9     "Normal distribution channel" means a chain of custody for
10 a prescription drug that goes, directly or by drop shipment,
11 from (i) a manufacturer of the prescription drug, (ii) that
12 manufacturer to that manufacturer's co-licensed partner, (iii)
13 that manufacturer to that manufacturer's third party logistics
14 provider, or (iv) that manufacturer to that manufacturer's
15 exclusive distributor to:
16         (1) a pharmacy or to other designated persons
17     authorized by law to dispense or administer the drug to a
18     patient;
19         (2) a wholesale distributor to a pharmacy or other
20     designated persons authorized by law to dispense or
21     administer the drug to a patient;
22         (3) a wholesale distributor to a chain pharmacy
23     warehouse to that chain pharmacy warehouse's intracompany
24     pharmacy to a patient or other designated persons
25     authorized by law to dispense or administer the drug to a
26     patient;

 

 

HB0333 - 18 - LRB096 03203 DRJ 13220 b

1         (4) a chain pharmacy warehouse to the chain pharmacy
2     warehouse's intracompany pharmacy or other designated
3     persons authorized by law to dispense or administer the
4     drug to the patient;
5         (5) an authorized distributor of record to one other
6     authorized distributor of record to an office-based health
7     care practitioner authorized by law to dispense or
8     administer the drug to the patient; or
9         (6) an authorized distributor to a pharmacy or other
10     persons licensed to dispense or administer the drug.
11     "Pedigree" means a document or electronic file containing
12 information that records each wholesale distribution of any
13 given prescription drug from the point of origin to the final
14 wholesale distribution point of any given prescription drug.
15     "Person" means and includes a natural person, partnership,
16 association or corporation.
17     "Pharmacy distributor" means any pharmacy licensed in this
18 State or hospital pharmacy that is engaged in the delivery or
19 distribution of prescription drugs either to any other pharmacy
20 licensed in this State or to any other person or entity
21 including, but not limited to, a wholesale drug distributor
22 engaged in the delivery or distribution of prescription drugs
23 who is involved in the actual, constructive, or attempted
24 transfer of a drug in this State to other than the ultimate
25 consumer except as otherwise provided for by law.
26     "Prescription drug" means any human drug, including any

 

 

HB0333 - 19 - LRB096 03203 DRJ 13220 b

1 biological product (except for blood and blood components
2 intended for transfusion or biological products that are also
3 medical devices), required by federal law or regulation to be
4 dispensed only by a prescription, including finished dosage
5 forms and bulk drug substances subject to Section 503 of the
6 Federal Food, Drug and Cosmetic Act.
7     "Repackage" means repackaging or otherwise changing the
8 container, wrapper, or labeling to further the distribution of
9 a prescription drug, excluding that completed by the pharmacist
10 responsible for dispensing the product to a patient.
11     "Secretary" means the Secretary of Financial and
12 Professional Regulation.
13     "Third party logistics provider" means anyone who
14 contracts with a prescription drug manufacturer to provide or
15 coordinate warehousing, distribution, or other services on
16 behalf of a manufacturer, but does not take title to the
17 prescription drug or have general responsibility to direct the
18 prescription drug's sale or disposition. A third party
19 logistics provider must be licensed as a wholesale distributor
20 under this Act and, in order to be considered part of the
21 normal distribution channel, must also be an authorized
22 distributor of record.
23     "Wholesale distribution" means the distribution of
24 prescription drugs to persons other than a consumer or patient,
25 but does not include any of the following:
26         (1) Intracompany sales of prescription drugs, meaning

 

 

HB0333 - 20 - LRB096 03203 DRJ 13220 b

1     (i) any transaction or transfer between any division,
2     subsidiary, parent, or affiliated or related company under
3     the common ownership and control of a corporate entity or
4     (ii) any transaction or transfer between co-licensees of a
5     co-licensed product.
6         (2) The sale, purchase, distribution, trade, or
7     transfer of a prescription drug or offer to sell, purchase,
8     distribute, trade, or transfer a prescription drug for
9     emergency medical reasons.
10         (3) The distribution of prescription drug samples by
11     manufacturers' representatives.
12         (4) Drug returns, when conducted by a hospital, health
13     care entity, or charitable institution in accordance with
14     federal regulation.
15         (5) The sale of minimal quantities of prescription
16     drugs by retail pharmacies to licensed practitioners for
17     office use.
18         (6) The sale, purchase, or trade of a drug, an offer to
19     sell, purchase, or trade a drug, or the dispensing of a
20     drug pursuant to a prescription.
21         (7) The sale, transfer, merger, or consolidation of all
22     or part of the business of a pharmacy or pharmacies from or
23     with another pharmacy or pharmacies, whether accomplished
24     as a purchase and sale of stock or business assets.
25         (8) The sale, purchase, distribution, trade, or
26     transfer of a prescription drug from one authorized

 

 

HB0333 - 21 - LRB096 03203 DRJ 13220 b

1     distributor of record to one additional authorized
2     distributor of record when the manufacturer has stated in
3     writing to the receiving authorized distributor of record
4     that the manufacturer is unable to supply the prescription
5     drug and the supplying authorized distributor of record
6     states in writing that the prescription drug being supplied
7     had until that time been exclusively in the normal
8     distribution channel.
9         (9) The delivery of or the offer to deliver a
10     prescription drug by a common carrier solely in the common
11     carrier's usual course of business of transporting
12     prescription drugs when the common carrier does not store,
13     warehouse, or take legal ownership of the prescription
14     drug.
15         (10) The sale or transfer from a retail pharmacy, mail
16     order pharmacy, or chain pharmacy warehouse of expired,
17     damaged, returned, or recalled prescription drugs to the
18     original manufacturer, the originating wholesale
19     distributor, or a third party returns processor.
20         (11) The donation of prescription drugs to the extent
21     permitted under the Prescription Drug Repository Program
22     Act.
23     "Wholesale drug distributor" means anyone engaged in the
24 wholesale distribution of prescription drugs, including
25 without limitation manufacturers; repackers; own label
26 distributors; jobbers; private label distributors; brokers;

 

 

HB0333 - 22 - LRB096 03203 DRJ 13220 b

1 warehouses, including manufacturers' and distributors'
2 warehouses; manufacturer's exclusive distributors; and
3 authorized distributors of record; drug wholesalers or
4 distributors; independent wholesale drug traders; specialty
5 wholesale distributors; third party logistics providers; and
6 retail pharmacies that conduct wholesale distribution; and
7 chain pharmacy warehouses that conduct wholesale distribution.
8 In order to be considered part of the normal distribution
9 channel, a wholesale distributor must also be an authorized
10 distributor of record.
11 (Source: P.A. 95-689, eff. 10-29-07.)
 
12     Section 93. The Senior Pharmaceutical Assistance Act is
13 amended by changing Section 10 as follows:
 
14     (320 ILCS 50/10)
15     Sec. 10. Definitions. In this Act:
16     "Manufacturer" includes:
17         (1) An entity that is engaged in (a) the production,
18     preparation, propagation, compounding, conversion, or
19     processing of prescription drug products (i) directly or
20     indirectly by extraction from substances of natural
21     origin, (ii) independently by means of chemical synthesis,
22     or (iii) by combination of extraction and chemical
23     synthesis; or (b) the packaging, repackaging, labeling or
24     re-labeling, or distribution of prescription drug

 

 

HB0333 - 23 - LRB096 03203 DRJ 13220 b

1     products.
2         (2) The entity holding legal title to or possession of
3     the national drug code number for the covered prescription
4     drug.
5     The term does not include a wholesale distributor of drugs,
6 drugstore chain organization, or retail pharmacy licensed by
7 the State. The term also does not include anyone who is engaged
8 in the packaging, repackaging, or labeling of prescription
9 drugs only to the extent required under the Prescription Drug
10 Repository Program Act.
11     "Prescription drug" means a drug that may be dispensed only
12 upon prescription by an authorized prescriber and that is
13 approved for safety and effectiveness as a prescription drug
14 under Section 505 or 507 of the Federal Food, Drug and Cosmetic
15 Act.
16     "Senior citizen" or "senior" means a person 65 years of age
17 or older.
18 (Source: P.A. 92-594, eff. 6-27-02.)
 
19     Section 94. The Illinois Food, Drug and Cosmetic Act is
20 amended by changing Sections 16 and 24 as follows:
 
21     (410 ILCS 620/16)  (from Ch. 56 1/2, par. 516)
22     Sec. 16. (a) The Director is hereby authorized to
23 promulgate regulations exempting from any labeling or
24 packaging requirement of this Act drugs and devices which are

 

 

HB0333 - 24 - LRB096 03203 DRJ 13220 b

1 (i) , in accordance with the practice of the trade, to be
2 processed, labeled or repacked in substantial quantities at
3 establishments other than those where originally processed or
4 packaged on condition that such drugs and devices are not
5 adulterated or misbranded under the provisions of this Act upon
6 removal from such processing, labeling or repacking
7 establishment or (ii) packaged, repackaged, or labeled to the
8 extent required under the Prescription Drug Repository Program
9 Act.
10     (b) Drugs and device labeling or packaging exemptions
11 adopted under the Federal Act and supplements thereto or
12 revisions thereof shall apply to drugs and devices in Illinois
13 except insofar as modified or rejected by regulations
14 promulgated by the Director.
15     (c) A drug intended for use by man which (A) is a
16 habit-forming drug to which Section 15 (d) applies; or (B)
17 because of its toxicity or other potentiality for harmful
18 effect or the method of its use or the collateral measures
19 necessary to its use is not safe for use except under the
20 supervision of a practitioner licensed by law to administer
21 such drug; or (C) is limited by an approved application under
22 Section 505 of the Federal Act or Section 17 of this Act to use
23 under the professional supervision of a practitioner licensed
24 by law to administer such drug, shall be dispensed only in
25 accordance with the provisions of the "Illinois Controlled
26 Substances Act". The act of dispensing a drug contrary to the

 

 

HB0333 - 25 - LRB096 03203 DRJ 13220 b

1 provisions of this paragraph shall be deemed to be an act which
2 results in a drug being misbranded while held for sale.
3     (d) Any drug dispensed by filling or refilling a written or
4 oral prescription of a practitioner licensed by law to
5 administer such drug shall be exempt from the requirements of
6 Section 15, except subsections (a), (k) and (l) and clauses (2)
7 and (3) of subsection (i), and the packaging requirements of
8 subsections (g), (h) and (q), if the drug bears a label
9 containing the proprietary name or names, or if there is none,
10 the established name or names of the drugs, the dosage and
11 quantity, unless the prescribing practitioner, in the interest
12 of the health of the patient, directs otherwise in writing, the
13 name and address of the dispenser, the serial number and date
14 of the prescription or of its filling, the name of the
15 prescriber and, if stated in the prescription, the name of the
16 patient, and the directions for use and the cautionary
17 statements, if any, contained in such prescription. This
18 exemption shall not apply to any drug dispensed in the course
19 of the conduct of business of dispensing drugs pursuant to
20 diagnosis by mail, or to a drug dispensed in violation of
21 subsection (a) of this Section.
22     (e) The Director may by regulation remove drugs subject to
23 Section 15 (d) and Section 17 from the requirements of
24 subsection (c) of this Section when such requirements are not
25 necessary for the protection of the public health.
26     (f) A drug which is subject to subsection (c) of this

 

 

HB0333 - 26 - LRB096 03203 DRJ 13220 b

1 Section shall be deemed to be misbranded if at any time before
2 dispensing its label fails to bear the statement "Caution:
3 Federal Law Prohibits Dispensing Without Prescription" or
4 "Caution: State Law Prohibits Dispensing Without
5 Prescription". A drug to which subsection (c) of this Section
6 does not apply shall be deemed to be misbranded if at any time
7 prior to dispensing its label bears the caution statement
8 quoted in the preceding sentence.
9     (g) Nothing in this Section shall be construed to relieve
10 any person from any requirement prescribed by or under
11 authority of law with respect to controlled substances now
12 included or which may hereafter be included within the
13 classifications of controlled substances cannabis as defined
14 in applicable Federal laws relating to controlled substances or
15 cannabis or the Cannabis Control Act.
16 (Source: P.A. 84-1308.)
 
17     (410 ILCS 620/24)  (from Ch. 56 1/2, par. 524)
18     Sec. 24. Nothing in this Act shall be construed to limit or
19 repeal any provisions of the Illinois Controlled Substances
20 Act, or the Methamphetamine Control and Community Protection
21 Act, or Section 3-3013 of the Counties Code.
22 (Source: P.A. 94-556, eff. 9-11-05.)
 
23     Section 95. The Illinois Controlled Substances Act is
24 amended by changing Sections 102 and 103 as follows:
 

 

 

HB0333 - 27 - LRB096 03203 DRJ 13220 b

1     (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
2     Sec. 102. Definitions. As used in this Act, unless the
3 context otherwise requires:
4     (a) "Addict" means any person who habitually uses any drug,
5 chemical, substance or dangerous drug other than alcohol so as
6 to endanger the public morals, health, safety or welfare or who
7 is so far addicted to the use of a dangerous drug or controlled
8 substance other than alcohol as to have lost the power of self
9 control with reference to his addiction.
10     (b) "Administer" means the direct application of a
11 controlled substance, whether by injection, inhalation,
12 ingestion, or any other means, to the body of a patient,
13 research subject, or animal (as defined by the Humane
14 Euthanasia in Animal Shelters Act) by:
15         (1) a practitioner (or, in his presence, by his
16     authorized agent),
17         (2) the patient or research subject at the lawful
18     direction of the practitioner, or
19         (3) a euthanasia technician as defined by the Humane
20     Euthanasia in Animal Shelters Act.
21     (c) "Agent" means an authorized person who acts on behalf
22 of or at the direction of a manufacturer, distributor, or
23 dispenser. It does not include a common or contract carrier,
24 public warehouseman or employee of the carrier or warehouseman.
25     (c-1) "Anabolic Steroids" means any drug or hormonal

 

 

HB0333 - 28 - LRB096 03203 DRJ 13220 b

1 substance, chemically and pharmacologically related to
2 testosterone (other than estrogens, progestins, and
3 corticosteroids) that promotes muscle growth, and includes:
4             (i) boldenone,
5             (ii) chlorotestosterone,
6             (iii) chostebol,
7             (iv) dehydrochlormethyltestosterone,
8             (v) dihydrotestosterone,
9             (vi) drostanolone,
10             (vii) ethylestrenol,
11             (viii) fluoxymesterone,
12             (ix) formebulone,
13             (x) mesterolone,
14             (xi) methandienone,
15             (xii) methandranone,
16             (xiii) methandriol,
17             (xiv) methandrostenolone,
18             (xv) methenolone,
19             (xvi) methyltestosterone,
20             (xvii) mibolerone,
21             (xviii) nandrolone,
22             (xix) norethandrolone,
23             (xx) oxandrolone,
24             (xxi) oxymesterone,
25             (xxii) oxymetholone,
26             (xxiii) stanolone,

 

 

HB0333 - 29 - LRB096 03203 DRJ 13220 b

1             (xxiv) stanozolol,
2             (xxv) testolactone,
3             (xxvi) testosterone,
4             (xxvii) trenbolone, and
5             (xxviii) any salt, ester, or isomer of a drug or
6         substance described or listed in this paragraph, if
7         that salt, ester, or isomer promotes muscle growth.
8     Any person who is otherwise lawfully in possession of an
9 anabolic steroid, or who otherwise lawfully manufactures,
10 distributes, dispenses, delivers, or possesses with intent to
11 deliver an anabolic steroid, which anabolic steroid is
12 expressly intended for and lawfully allowed to be administered
13 through implants to livestock or other nonhuman species, and
14 which is approved by the Secretary of Health and Human Services
15 for such administration, and which the person intends to
16 administer or have administered through such implants, shall
17 not be considered to be in unauthorized possession or to
18 unlawfully manufacture, distribute, dispense, deliver, or
19 possess with intent to deliver such anabolic steroid for
20 purposes of this Act.
21     (d) "Administration" means the Drug Enforcement
22 Administration, United States Department of Justice, or its
23 successor agency.
24     (e) "Control" means to add a drug or other substance, or
25 immediate precursor, to a Schedule under Article II of this Act
26 whether by transfer from another Schedule or otherwise.

 

 

HB0333 - 30 - LRB096 03203 DRJ 13220 b

1     (f) "Controlled Substance" means a drug, substance, or
2 immediate precursor in the Schedules of Article II of this Act.
3     (g) "Counterfeit substance" means a controlled substance,
4 which, or the container or labeling of which, without
5 authorization bears the trademark, trade name, or other
6 identifying mark, imprint, number or device, or any likeness
7 thereof, of a manufacturer, distributor, or dispenser other
8 than the person who in fact manufactured, distributed, or
9 dispensed the substance.
10     (h) "Deliver" or "delivery" means the actual, constructive
11 or attempted transfer of possession of a controlled substance,
12 with or without consideration, whether or not there is an
13 agency relationship. The term does not include the donation of
14 prescription drugs to the extent permitted under the
15 Prescription Drug Repository Program Act.
16     (i) "Department" means the Illinois Department of Human
17 Services (as successor to the Department of Alcoholism and
18 Substance Abuse) or its successor agency.
19     (j) "Department of State Police" means the Department of
20 State Police of the State of Illinois or its successor agency.
21     (k) "Department of Corrections" means the Department of
22 Corrections of the State of Illinois or its successor agency.
23     (l) "Department of Professional Regulation" means the
24 Department of Professional Regulation of the State of Illinois
25 or its successor agency.
26     (m) "Depressant" or "stimulant substance" means:

 

 

HB0333 - 31 - LRB096 03203 DRJ 13220 b

1         (1) a drug which contains any quantity of (i)
2     barbituric acid or any of the salts of barbituric acid
3     which has been designated as habit forming under section
4     502 (d) of the Federal Food, Drug, and Cosmetic Act (21
5     U.S.C. 352 (d)); or
6         (2) a drug which contains any quantity of (i)
7     amphetamine or methamphetamine and any of their optical
8     isomers; (ii) any salt of amphetamine or methamphetamine or
9     any salt of an optical isomer of amphetamine; or (iii) any
10     substance which the Department, after investigation, has
11     found to be, and by rule designated as, habit forming
12     because of its depressant or stimulant effect on the
13     central nervous system; or
14         (3) lysergic acid diethylamide; or
15         (4) any drug which contains any quantity of a substance
16     which the Department, after investigation, has found to
17     have, and by rule designated as having, a potential for
18     abuse because of its depressant or stimulant effect on the
19     central nervous system or its hallucinogenic effect.
20     (n) (Blank).
21     (o) "Director" means the Director of the Department of
22 State Police or the Department of Professional Regulation or
23 his designated agents.
24     (p) "Dispense" means to deliver a controlled substance to
25 an ultimate user or research subject by or pursuant to the
26 lawful order of a prescriber, including the prescribing,

 

 

HB0333 - 32 - LRB096 03203 DRJ 13220 b

1 administering, packaging, labeling, or compounding necessary
2 to prepare the substance for that delivery.
3     (q) "Dispenser" means a practitioner who dispenses.
4     (r) "Distribute" means to deliver, other than by
5 administering or dispensing, a controlled substance.
6     (s) "Distributor" means a person who distributes.
7     (t) "Drug" means (1) substances recognized as drugs in the
8 official United States Pharmacopoeia, Official Homeopathic
9 Pharmacopoeia of the United States, or official National
10 Formulary, or any supplement to any of them; (2) substances
11 intended for use in diagnosis, cure, mitigation, treatment, or
12 prevention of disease in man or animals; (3) substances (other
13 than food) intended to affect the structure of any function of
14 the body of man or animals and (4) substances intended for use
15 as a component of any article specified in clause (1), (2), or
16 (3) of this subsection. It does not include devices or their
17 components, parts, or accessories.
18     (t-5) "Euthanasia agency" means an entity certified by the
19 Department of Professional Regulation for the purpose of animal
20 euthanasia that holds an animal control facility license or
21 animal shelter license under the Animal Welfare Act. A
22 euthanasia agency is authorized to purchase, store, possess,
23 and utilize Schedule II nonnarcotic and Schedule III
24 nonnarcotic drugs for the sole purpose of animal euthanasia.
25     (t-10) "Euthanasia drugs" means Schedule II or Schedule III
26 substances (nonnarcotic controlled substances) that are used

 

 

HB0333 - 33 - LRB096 03203 DRJ 13220 b

1 by a euthanasia agency for the purpose of animal euthanasia.
2     (u) "Good faith" means the prescribing or dispensing of a
3 controlled substance by a practitioner in the regular course of
4 professional treatment to or for any person who is under his
5 treatment for a pathology or condition other than that
6 individual's physical or psychological dependence upon or
7 addiction to a controlled substance, except as provided herein:
8 and application of the term to a pharmacist shall mean the
9 dispensing of a controlled substance pursuant to the
10 prescriber's order which in the professional judgment of the
11 pharmacist is lawful. The pharmacist shall be guided by
12 accepted professional standards including, but not limited to
13 the following, in making the judgment:
14         (1) lack of consistency of doctor-patient
15     relationship,
16         (2) frequency of prescriptions for same drug by one
17     prescriber for large numbers of patients,
18         (3) quantities beyond those normally prescribed,
19         (4) unusual dosages,
20         (5) unusual geographic distances between patient,
21     pharmacist and prescriber,
22         (6) consistent prescribing of habit-forming drugs.
23     (u-1) "Home infusion services" means services provided by a
24 pharmacy in compounding solutions for direct administration to
25 a patient in a private residence, long-term care facility, or
26 hospice setting by means of parenteral, intravenous,

 

 

HB0333 - 34 - LRB096 03203 DRJ 13220 b

1 intramuscular, subcutaneous, or intraspinal infusion.
2     (v) "Immediate precursor" means a substance:
3         (1) which the Department has found to be and by rule
4     designated as being a principal compound used, or produced
5     primarily for use, in the manufacture of a controlled
6     substance;
7         (2) which is an immediate chemical intermediary used or
8     likely to be used in the manufacture of such controlled
9     substance; and
10         (3) the control of which is necessary to prevent,
11     curtail or limit the manufacture of such controlled
12     substance.
13     (w) "Instructional activities" means the acts of teaching,
14 educating or instructing by practitioners using controlled
15 substances within educational facilities approved by the State
16 Board of Education or its successor agency.
17     (x) "Local authorities" means a duly organized State,
18 County or Municipal peace unit or police force.
19     (y) "Look-alike substance" means a substance, other than a
20 controlled substance which (1) by overall dosage unit
21 appearance, including shape, color, size, markings or lack
22 thereof, taste, consistency, or any other identifying physical
23 characteristic of the substance, would lead a reasonable person
24 to believe that the substance is a controlled substance, or (2)
25 is expressly or impliedly represented to be a controlled
26 substance or is distributed under circumstances which would

 

 

HB0333 - 35 - LRB096 03203 DRJ 13220 b

1 lead a reasonable person to believe that the substance is a
2 controlled substance. For the purpose of determining whether
3 the representations made or the circumstances of the
4 distribution would lead a reasonable person to believe the
5 substance to be a controlled substance under this clause (2) of
6 subsection (y), the court or other authority may consider the
7 following factors in addition to any other factor that may be
8 relevant:
9         (a) statements made by the owner or person in control
10     of the substance concerning its nature, use or effect;
11         (b) statements made to the buyer or recipient that the
12     substance may be resold for profit;
13         (c) whether the substance is packaged in a manner
14     normally used for the illegal distribution of controlled
15     substances;
16         (d) whether the distribution or attempted distribution
17     included an exchange of or demand for money or other
18     property as consideration, and whether the amount of the
19     consideration was substantially greater than the
20     reasonable retail market value of the substance.
21     Clause (1) of this subsection (y) shall not apply to a
22 noncontrolled substance in its finished dosage form that was
23 initially introduced into commerce prior to the initial
24 introduction into commerce of a controlled substance in its
25 finished dosage form which it may substantially resemble.
26     Nothing in this subsection (y) prohibits the dispensing or

 

 

HB0333 - 36 - LRB096 03203 DRJ 13220 b

1 distributing of noncontrolled substances by persons authorized
2 to dispense and distribute controlled substances under this
3 Act, provided that such action would be deemed to be carried
4 out in good faith under subsection (u) if the substances
5 involved were controlled substances.
6     Nothing in this subsection (y) or in this Act prohibits the
7 manufacture, preparation, propagation, compounding,
8 processing, packaging, advertising or distribution of a drug or
9 drugs by any person registered pursuant to Section 510 of the
10 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
11     (y-1) "Mail-order pharmacy" means a pharmacy that is
12 located in a state of the United States, other than Illinois,
13 that delivers, dispenses or distributes, through the United
14 States Postal Service or other common carrier, to Illinois
15 residents, any substance which requires a prescription.
16     (z) "Manufacture" means the production, preparation,
17 propagation, compounding, conversion or processing of a
18 controlled substance other than methamphetamine, either
19 directly or indirectly, by extraction from substances of
20 natural origin, or independently by means of chemical
21 synthesis, or by a combination of extraction and chemical
22 synthesis, and includes any packaging or repackaging of the
23 substance or labeling of its container, except that this term
24 does not include:
25         (1) by an ultimate user, the preparation or compounding
26     of a controlled substance for his own use; or

 

 

HB0333 - 37 - LRB096 03203 DRJ 13220 b

1         (2) by a practitioner, or his authorized agent under
2     his supervision, the preparation, compounding, packaging,
3     or labeling of a controlled substance:
4             (a) as an incident to his administering or
5         dispensing of a controlled substance in the course of
6         his professional practice; or
7             (b) as an incident to lawful research, teaching or
8         chemical analysis and not for sale; or .
9         (3) the packaging, repackaging, or labeling of
10     prescription drugs only to the extent required under the
11     Prescription Drug Repository Program Act.
12     (z-1) (Blank).
13     (aa) "Narcotic drug" means any of the following, whether
14 produced directly or indirectly by extraction from substances
15 of natural origin, or independently by means of chemical
16 synthesis, or by a combination of extraction and chemical
17 synthesis:
18         (1) opium and opiate, and any salt, compound,
19     derivative, or preparation of opium or opiate;
20         (2) any salt, compound, isomer, derivative, or
21     preparation thereof which is chemically equivalent or
22     identical with any of the substances referred to in clause
23     (1), but not including the isoquinoline alkaloids of opium;
24         (3) opium poppy and poppy straw;
25         (4) coca leaves and any salts, compound, isomer, salt
26     of an isomer, derivative, or preparation of coca leaves

 

 

HB0333 - 38 - LRB096 03203 DRJ 13220 b

1     including cocaine or ecgonine, and any salt, compound,
2     isomer, derivative, or preparation thereof which is
3     chemically equivalent or identical with any of these
4     substances, but not including decocainized coca leaves or
5     extractions of coca leaves which do not contain cocaine or
6     ecgonine (for the purpose of this paragraph, the term
7     "isomer" includes optical, positional and geometric
8     isomers).
9     (bb) "Nurse" means a registered nurse licensed under the
10 Nurse Practice Act.
11     (cc) (Blank).
12     (dd) "Opiate" means any substance having an addiction
13 forming or addiction sustaining liability similar to morphine
14 or being capable of conversion into a drug having addiction
15 forming or addiction sustaining liability.
16     (ee) "Opium poppy" means the plant of the species Papaver
17 somniferum L., except its seeds.
18     (ff) "Parole and Pardon Board" means the Parole and Pardon
19 Board of the State of Illinois or its successor agency.
20     (gg) "Person" means any individual, corporation,
21 mail-order pharmacy, government or governmental subdivision or
22 agency, business trust, estate, trust, partnership or
23 association, or any other entity.
24     (hh) "Pharmacist" means any person who holds a license or
25 certificate of registration as a registered pharmacist, a local
26 registered pharmacist or a registered assistant pharmacist

 

 

HB0333 - 39 - LRB096 03203 DRJ 13220 b

1 under the Pharmacy Practice Act.
2     (ii) "Pharmacy" means any store, ship or other place in
3 which pharmacy is authorized to be practiced under the Pharmacy
4 Practice Act.
5     (jj) "Poppy straw" means all parts, except the seeds, of
6 the opium poppy, after mowing.
7     (kk) "Practitioner" means a physician licensed to practice
8 medicine in all its branches, dentist, optometrist,
9 podiatrist, veterinarian, scientific investigator, pharmacist,
10 physician assistant, advanced practice nurse, licensed
11 practical nurse, registered nurse, hospital, laboratory, or
12 pharmacy, or other person licensed, registered, or otherwise
13 lawfully permitted by the United States or this State to
14 distribute, dispense, conduct research with respect to,
15 administer or use in teaching or chemical analysis, a
16 controlled substance in the course of professional practice or
17 research.
18     (ll) "Pre-printed prescription" means a written
19 prescription upon which the designated drug has been indicated
20 prior to the time of issuance.
21     (mm) "Prescriber" means a physician licensed to practice
22 medicine in all its branches, dentist, optometrist, podiatrist
23 or veterinarian who issues a prescription, a physician
24 assistant who issues a prescription for a Schedule III, IV, or
25 V controlled substance in accordance with Section 303.05 and
26 the written guidelines required under Section 7.5 of the

 

 

HB0333 - 40 - LRB096 03203 DRJ 13220 b

1 Physician Assistant Practice Act of 1987, or an advanced
2 practice nurse with prescriptive authority delegated under
3 Section 65-40 of the Nurse Practice Act and in accordance with
4 Section 303.05 and a written collaborative agreement under
5 Section 65-35 of the Nurse Practice Act.
6     (nn) "Prescription" means a lawful written, facsimile, or
7 verbal order of a physician licensed to practice medicine in
8 all its branches, dentist, podiatrist or veterinarian for any
9 controlled substance, of an optometrist for a Schedule III, IV,
10 or V controlled substance in accordance with Section 15.1 of
11 the Illinois Optometric Practice Act of 1987, of a physician
12 assistant for a Schedule III, IV, or V controlled substance in
13 accordance with Section 303.05 and the written guidelines
14 required under Section 7.5 of the Physician Assistant Practice
15 Act of 1987, or of an advanced practice nurse with prescriptive
16 authority delegated under Section 65-40 of the Nurse Practice
17 Act who issues a prescription for a Schedule III, IV, or V
18 controlled substance in accordance with Section 303.05 and a
19 written collaborative agreement under Section 65-35 of the
20 Nurse Practice Act.
21     (oo) "Production" or "produce" means manufacture,
22 planting, cultivating, growing, or harvesting of a controlled
23 substance other than methamphetamine.
24     (pp) "Registrant" means every person who is required to
25 register under Section 302 of this Act.
26     (qq) "Registry number" means the number assigned to each

 

 

HB0333 - 41 - LRB096 03203 DRJ 13220 b

1 person authorized to handle controlled substances under the
2 laws of the United States and of this State.
3     (rr) "State" includes the State of Illinois and any state,
4 district, commonwealth, territory, insular possession thereof,
5 and any area subject to the legal authority of the United
6 States of America.
7     (ss) "Ultimate user" means a person who lawfully possesses
8 a controlled substance for his own use or for the use of a
9 member of his household or for administering to an animal owned
10 by him or by a member of his household.
11 (Source: P.A. 94-556, eff. 9-11-05; 95-242, eff. 1-1-08;
12 95-639, eff. 10-5-07; 95-689, eff. 10-29-07; 95-876, eff.
13 8-21-08.)
 
14     (720 ILCS 570/103)  (from Ch. 56 1/2, par. 1103)
15     Sec. 103. Scope of Act. Nothing in this Act limits the
16 lawful authority granted by the Medical Practice Act of 1987,
17 the Nurse Practice Act, the Illinois Optometric Practice Act of
18 1987, or the Pharmacy Practice Act, or Section 3-3013 of the
19 Counties Code.
20 (Source: P.A. 95-242, eff. 1-1-08; 95-639, eff. 10-5-07;
21 95-689, eff. 10-29-07; 95-876, eff. 8-21-08.)
 
22     Section 96. The Cannabis and Controlled Substances Tort
23 Claims Act is amended by changing Section 3 as follows:
 

 

 

HB0333 - 42 - LRB096 03203 DRJ 13220 b

1     (740 ILCS 20/3)  (from Ch. 70, par. 903)
2     Sec. 3. Definitions. As used in this Act, unless the
3 context otherwise requires:
4     "Cannabis" includes marihuana, hashish, and other
5 substances that are identified as including any parts of the
6 plant Cannabis Sativa, whether growing or not, the seeds of
7 that plant, the resin extracted from any part of that plant,
8 and any compound, manufacture, salt, derivative, mixture, or
9 preparation of that plant, its seeds, or resin, including
10 tetrahydrocannabinol (THC) and all other cannabinol
11 derivatives, including its naturally occurring or
12 synthetically produced ingredients, whether produced directly
13 or indirectly by extraction, independently by means of chemical
14 synthesis, or by a combination of extraction and chemical
15 synthesis. "Cannabis" does not include the mature stalks of
16 that plant, fiber produced from those stalks, oil or cake made
17 from the seeds of that plant, any other compound, manufacture,
18 salt, derivative, mixture, or preparation of mature stalks
19 (except the extracted resin), fiber, oil or cake, or the
20 sterilized seeds of that plant that are incapable of
21 germination.
22     "Controlled substance" means a drug, substance, or
23 immediate precursor in the Schedules of Article II of the
24 Illinois Controlled Substances Act.
25     "Counterfeit substance" means a controlled substance or
26 the container or labeling of a controlled substance that,

 

 

HB0333 - 43 - LRB096 03203 DRJ 13220 b

1 without authorization, bears the trademark, trade name, or
2 other identifying mark, imprint, number, device, or any
3 likeness thereof of a manufacturer, distributor, or dispenser
4 other than the person who in fact manufactured, distributed, or
5 dispensed the substance.
6     "Deliver" or "delivery" means the actual, constructive, or
7 attempted transfer of possession of a controlled substance or
8 cannabis, with or without consideration, whether or not there
9 is an agency relationship. The term does not include the
10 donation of prescription drugs to the extent permitted under
11 the Prescription Drug Repository Program Act.
12     "Manufacture" means the production, preparation,
13 propagation, compounding, conversion, or processing of a
14 controlled substance, either directly or indirectly, by
15 extraction from substances of natural origin, independently by
16 means of chemical synthesis, or by a combination of extraction
17 and chemical synthesis, and includes any packaging or
18 repackaging of the substance or labeling of its container,
19 except that the term does not include:
20         (1) by an ultimate user, the preparation or compounding
21     of a controlled substance for his own use;
22         (2) by a practitioner or his authorized agent under his
23     supervision, the preparation, compounding, packaging, or
24     labeling of a controlled substance: ;
25             (A) as an incident to his administering or
26         dispensing of a controlled substance in the course of

 

 

HB0333 - 44 - LRB096 03203 DRJ 13220 b

1         his professional practice; or
2             (B) as an incident to lawful research, teaching or
3         chemical analysis and not for sale; or
4         (3) the preparation, compounding, packaging, or
5     labeling of cannabis as an incident to lawful research,
6     teaching, or chemical analysis and not for sale; or .
7         (4) the packaging, repackaging, or labeling of
8     prescription drugs only to the extent required under the
9     Prescription Drug Repository Program Act.
10     "Owner" means a person who has possession of or any
11 interest whatsoever in the property involved.
12     "Person" means an individual, a corporation, a government,
13 a governmental subdivision or agency, a business trust, an
14 estate, a trust, a partnership or association, or any other
15 entity.
16     "Production" means planting, cultivating, tending, or
17 harvesting.
18     "Property" means real property, including things growing
19 on, affixed to, and found in land, and tangible or intangible
20 personal property, including rights, services, privileges,
21 interests, claims, and securities.
22 (Source: P.A. 87-544; revised 10-23-08.)

 

 

HB0333 - 45 - LRB096 03203 DRJ 13220 b

1 INDEX
2 Statutes amended in order of appearance
3     New Act
4     55 ILCS 5/3-3013 from Ch. 34, par. 3-3013
5     225 ILCS 85/4 from Ch. 111, par. 4124
6     225 ILCS 120/15 from Ch. 111, par. 8301-15
7     320 ILCS 50/10
8     410 ILCS 620/16 from Ch. 56 1/2, par. 516
9     410 ILCS 620/24 from Ch. 56 1/2, par. 524
10     720 ILCS 570/102 from Ch. 56 1/2, par. 1102
11     720 ILCS 570/103 from Ch. 56 1/2, par. 1103
12     740 ILCS 20/3 from Ch. 70, par. 903